Ann: Phase II Alzheimer's Disease Trial - results, page-77

Thanks for that!

Re the Xanahes trial - I agree thats the primary purpose but looks like they will be doing some cognitive testing at the same time (see below). I also agree re time frame/funding... if June results are positive I might be in for the haul.

The purpose of this study is to evaluate the safety and tolerability of Xanamem 20 mg and 30 mg once daily (QD) from Baseline to End of Treatment (EOT) as measured by multiple, objective items of overall safety and Nerve Function Monitoring (NFM). Additional exploratory objectives consist of CogState electronic cognitive measurements, cortisol measurements, serum PK and optional Cerebrospinal Fluid (CSF) samples.